In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations

Antimicrobial Agents and Chemotherapy
Samuel A ShelburneRichard J Hamill

Abstract

This study employs time-kill techniques to examine the most common drug combinations used in the therapy of methicillin-resistant Staphylococcus aureus (MRSA) infections, vancomycin plus either gentamicin or rifampin. Community-associated MRSA were more likely to be synergistically inhibited by combinations of vancomycin and gentamicin versus vancomycin alone compared to inhibition associated with hospital-acquired strains.

References

Oct 27, 1978·JAMA : the Journal of the American Medical Association·R J FavilleP G Quie
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P M Small, H F Chambers
Jul 1, 1989·Antimicrobial Agents and Chemotherapy·C J Hackbarth, H F Chambers
Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Apr 1, 1988·Clinical Microbiology Reviews·H F Chambers
Jul 1, 1983·Reviews of Infectious Diseases·P Van der AuweraJ Klastersky
Feb 1, 1983·The Journal of Infectious Diseases·C W Norden, M Shaffer
Jun 1, 1981·Antimicrobial Agents and Chemotherapy·C Watanakunakorn, J C Guerriero
May 1, 1994·Antimicrobial Agents and Chemotherapy·R O Darouiche, R J Hamill
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G A Ayliffe
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·F LaurentJ P Flandrois
Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J FortúnS Moreno
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T S NaimiK E Smith
Jul 11, 2002·Diagnostic Microbiology and Infectious Disease·Laurel S AlmerRobert K Flamm
Nov 1, 2002·Journal of Clinical Microbiology·Keiko OkumaKeiichi Hiramatsu
Dec 11, 2003·JAMA : the Journal of the American Medical Association·Timothy S NaimiRuth Lynfield

❮ Previous
Next ❯

Citations

Dec 13, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M H Kollef
Dec 3, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L Stevens
Jan 20, 2012·The Journal of Antimicrobial Chemotherapy·Hung-Jen TangYin-Ching Chuang
Nov 29, 2007·The Pediatric Infectious Disease Journal·Monica I ArduraPablo J Sánchez
Aug 13, 2008·Antimicrobial Agents and Chemotherapy·Alexandros IkonomidisSpyros Pournaras
Dec 14, 2007·Journal of Clinical Microbiology·Chia-Yu ChiChing-Chuan Liu
Dec 3, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G LuoA S Ibrahim
Jun 14, 2013·Clinical & Developmental Immunology·Elizabeth A MarchantPascal M Lavoie
Jan 31, 2006·Expert Review of Anti-infective Therapy·John F Marcinak, Arthur L Frank
Oct 13, 2007·Expert Opinion on Pharmacotherapy·Evelina Tacconelli, Maria A Cataldo
May 11, 2012·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Wen-Shiann WuHung-Jen Tang
Mar 29, 2016·MedChemComm·Nishad Thamban Chandrika, Sylvie Garneau-Tsodikova
Apr 24, 2010·Bioorganic & Medicinal Chemistry Letters·Smritilekha BeraFrank Schweizer
Mar 4, 2009·Enfermedades infecciosas y microbiología clínica·Francisco GudiolUNKNOWN Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Mar 26, 2008·Critical Care Clinics·Burke A Cunha
Jul 17, 2007·International Journal of Antimicrobial Agents·M S Morgan
Nov 22, 2005·Infectious Disease Clinics of North America·Sheldon L Kaplan
Dec 28, 2006·Journal of the American Academy of Dermatology·Dirk M Elston
Jan 3, 2007·The Journal of Infection·Naval G DaverA Clinton White
Dec 17, 2009·Angewandte Chemie·John B BremnerDavid I Rhodes
Aug 29, 2006·Seminars in Pediatric Infectious Diseases·Sheldon L Kaplan
Mar 16, 2013·FEMS Microbiology Ecology·Terrence H BellCharles W Greer
Sep 29, 2006·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Blanca E GonzalezKristina G Hulten
Nov 1, 2005·Current Opinion in Infectious Diseases·Michael W Ellis, James S Lewis
Aug 30, 2020·Journal of Orthopaedic Surgery and Research·Øystein Espeland KarlsenMarianne Westberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.